SOPs for Injectables V 2.0

To define the procedure for the systematic and GMP-compliant formulation development of intravenous (IV) injections. This SOP ensures that the formulation is robust, sterile, isotonic, and stable for parenteral administration while meeting regulatory expectations.
Click to read the full article.

To establish a standardized, GMP-compliant procedure for the development of intramuscular (IM) injection formulations that are safe, stable, and effective for parenteral administration. This SOP covers both aqueous and oily vehicles suitable for IM administration.
Click to read the full article.

To define the procedure for formulation development of subcutaneous (SC) injections with focus on safety, patient comfort, drug stability, and regulatory compliance in line with WHO, GMP, and ICH standards.
Click to read the full article.

To establish a standard procedure for the formulation development of intraosseous (IO) injections, ensuring rapid systemic absorption, compatibility with bone marrow physiology, and compliance with GMP and ICH guidelines.
Click to read the full article.

To define the standard procedure for formulation development of intradermal (ID) injections, ensuring compliance with regulatory requirements and focusing on safety, efficacy, and compatibility with the dermal layer.
Click to read the full article.

To establish a standard procedure for the development of prefilled syringe (PFS) formulations and conduct compatibility studies to ensure product safety, container-closure integrity, and stability.
Click to read the full article.

To define a systematic and compliant approach for conducting stability studies of sterile injectable products during the development phase to establish shelf life, support formulation development, and determine storage conditions.
Click to read the full article.

To define the procedure for conducting compatibility studies between sterile injectable formulations and their respective container closure systems to ensure integrity, product stability, and safety in compliance with GMP, ICH Q1A, and USP standards.
Click to read the full article.

To establish a standardized procedure for identifying, evaluating, and managing risks associated with the development of sterile injection products in accordance with ICH Q9 guidelines, Good Manufacturing Practices (GMP), and Quality by Design (QbD) principles.
Click to read the full article.

To establish a standardized procedure for evaluating and optimizing the viscosity of sterile injectable formulations to ensure ease of administration, patient compliance, and dosage uniformity as per pharmacopoeial and regulatory requirements.
Click to read the full article.